Screener
ADMA Biologics ADMA Compensation and benefits
Compensation and benefits at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Gain on sale of plasma centers | (7,980) | - |
| Loss on disposal of fixed assets | 42 | - |
| Deferred income tax provision | 3,295 | 5,045 |
| Stock-based compensation | 12,464 | 9,587 |
| Amortization of debt discount | 383 | 350 |
| Loss on extinguishment of debt | - | 1,159 |
| Amortization of license revenue | (71) | (71) |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's compensation and benefits?
- ADMA Biologics (ADMA) reported compensation and benefits of $75K in Q2 2026.
- How has ADMA Biologics's compensation and benefits changed year-over-year?
- ADMA Biologics's compensation and benefits increased by 47.1% year-over-year, from $51K to $75K.
- What is the long-term trend for ADMA Biologics's compensation and benefits?
- Over 2 years (2023 to 2025), ADMA Biologics's compensation and benefits has grown at a 56.3% compound annual growth rate (CAGR), from $6.19M to $15.11M.
- What does compensation and benefits mean?
- Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.
Ask your AI about ADMA Biologics's compensation and benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude